Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors, Radiation Toxicity
In brief
RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving neurocognitive function in patients who have undergone radiation therapy for primary brain tumor or brain metastases.
Key facts
- Study ID
- NCT00070161
- Run by
- Wake Forest University Health Sciences
- People needed
- 68
- Starts
- 2001-07-01
- Expected to finish
- 2012-08-01
- Last updated by the study team
- 2021-09-09
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCOP - Western Regional, Arizona — Phoenix, Arizona, United States
- Regional Radiation Oncology Center at Rome — Rome, Georgia, United States
- Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
- CCOP - Upstate Carolina — Spartanburg, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.